Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease

被引：0
|
作者：
HUANG, X. I. A. O. Y. I. N. G. [1 ]
LI, X. I. A. O. F. E. I. [2 ]
机构：
[1] YiWu Cent Hosp, Emergency Dept, Jinhua, Zhejiang, Peoples R China
[2] YiWu Cent Hosp, Dept Infect Dis, Jinhua, Zhejiang, Peoples R China
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2022年 / 20卷 / 05期
关键词：
D O I：
10.1016/j.cgh.2021.05.013
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
下载
收藏
页码：E1216 / E1216
页数：1
相关论文
共 50 条
  • [1] Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease
    Narula, Neeraj
    Wong, Emily C. L.
    Dulai, Parambir S.
    Sengupta, Neil K.
    Marshall, John K.
    Colombel, Jean-Frederic
    Reinisch, Walter
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (07) : 1579 - +
  • [2] Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naive Crohn's Disease
    Wong, Emily C. L.
    Dulai, Parambir S.
    Marshall, John K.
    Jairath, Vipul
    Reinisch, Walter
    Narula, Neeraj
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (07) : 1015 - 1023
  • [3] Comparison of Surgical Rates in Biologic Naive Crohn's Disease Patients on Ustekinumab and Vedolizumab
    Mohammed, Abdul
    Alchirazi, Khaled Alsabbagh
    Hamid, Osama
    Eltelbany, Ahmed
    Garg, Rajat
    Paranji, Neethi
    Gonzaga, Ernesto Robalino
    Singh, Amandeep
    Kais, Susan
    Regueiro, Miguel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S706 - S707
  • [4] Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naive Patients
    Aliyev, Elmar R.
    Hay, Joel W.
    Hwang, Caroline
    PHARMACOTHERAPY, 2019, 39 (02): : 118 - 128
  • [5] Ustekinumab vs adalimumab for Crohn's disease
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (09): : 793 - 793
  • [6] Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn's disease
    Jung, Y. S.
    Han, M.
    Park, S.
    Cheon, J. H.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S374 - S374
  • [7] Infliximab Infusion Patterns in Patients with Crohn's Disease Naive to Biologic Therapy: An Analysis of a National Health Plan
    Mueller, C. Schmeichel
    Denny, L.
    Tkacz, J.
    Reutsch, C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S412 - S412
  • [8] Are clinical decision support tools for vedolizumab and ustekinumab in biologic naive patients with Crohn's disease drug-specific?
    Kim, J. E.
    Won, H.
    Kim, Y. H.
    Kim, E. R.
    Hong, S. N.
    Chang, D. K.
    Won, Hojeong
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I370 - I370
  • [9] Are clinical decision support tools for vedolizumab and ustekinumab in biologic naive patients with Crohn's disease drug-specific?
    Kim, J. E.
    Won, H.
    Kim, Y. H.
    Kim, E. R.
    Hong, S. N.
    Chang, D. K.
    Won, Hojeong
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I370 - I370
  • [10] Infliximab vs. Adalimumab for Crohn's disease
    Mulani, P.
    Chao, J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (10) : 1265 - 1266
12345